SIMCERE PHARMA
Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million.
SIMCERE PHARMA
Social Links:
Industry:
Biotechnology Manufacturing
Founded:
1995-01-01
Address:
Nanjing, Jiangsu, China
Country:
China
Website Url:
http://www.simcere.com
Total Employee:
1001+
Status:
Active
Contact:
+025-85566666
Email Addresses:
[email protected]
Total Funding:
600 M CNY
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Mobile Non Scaleable Content ASP.NET IIS DigiCert SSL ASP.NET 4.0 IIS 8 RapidSSL
Similar Organizations
Advanced Enzymes
Advanced Enzyme is a research driven company manufacturing enzymes and probiotics and dedicated to marketing eco-safe solutions.
Aesica Pharmaceuticals
Aesica Pharmaceuticals Ltd. develops, manufactures, and supplies active pharmaceutical ingredients, formulations, and custom synthesis
B&T Biotech
B&T Biotech is a manufacturer of aquatic microbial preparation products.
Centre for Cellular and Molecular Platforms
Centre for Cellular and Molecular Platforms is an enabler or catalyst of cutting-edge research and innovation in the life sciences.
Enologica Vason
Enologica Vason is a family-run business that offers specialized services for companies in the beverage industry.
Excell Biology
Excell Biology is a supplier of raw materials to the biopharmaceutical and precision medicine industries.
Graphenea
Graphenea is leader in graphene production, producing CVD graphene wafers and Graphene Oxide materials.
Happiness Development Group
Happiness Development Group is an innovative China-based nutraceutical and dietary supplements producer.
Hemmo Pharmaceuticals
Hemmo Pharma is a manufacturer of Peptide-based pharmaceuticals, supplying quality products for the last 37 years.
Innovita Biological Technology
Innovita Biological Technology provides R&D, manufacturing, marketing and after-sales service of In-vitro diagnostic tests.
Kuaifawu.com
Kuaifawu.com provides company registration, taxation, patent and trademark registration to Chinese start-ups and SMEs.
Microdermis
Microdermis manufactures and markets skin care products for skin repair and protection, antimicrobial, and dental skin care.
Neusoft Medical Systems
Neusoft Medical Systems is a leading manufacturer of medical equipment and service in china.
Norman Biological Technology
Norman Biological Technology is a manufacturer of automated chemiluminescence system.
Redbud Labs
Redbud Labs develops and manufactures MEMS and microfluidics technologies for the life science industry.
Seegene
Seegene, Inc. is an in-vitro diagnostics (IVD) company that has been turning concepts into products through its pioneering R&D activities.
Setsuro Tech
Setsuro Tech is a Business Information Systems service platform.
Sun Pharmaceutical Industries
Sun Pharmaceutical Industries is a specialized generic pharmaceutical firm that provides high-quality, low-cost medicines.
Symbiosis Pharmaceutical Services
A leading GMP contract manufacturer of novel injectable pharmaceuticals for use in clinical trials.
Tokiwa Bio
Tokiwa Bio is a manufacturing and development company.
United Water
United Water is a Chinese water and wastewater treatment provider.
Wuxi Vision Pro
Wuxi Vision Pro is an emerging in ophthalmic materials and devices.
Xinheng
Xinheng manufactures and sells automatic Chinese medicine dispensing & decoction equipment.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
HosenCare Brothers
HosenCare Brothers investment in Series B - Simcere Pharma
Jolmo Capital
Jolmo Capital investment in Series B - Simcere Pharma
CITIC Medical Fund
CITIC Medical Fund investment in Series B - Simcere Pharma
Nanjing Innovation Capital Group
Nanjing Innovation Capital Group investment in Series B - Simcere Pharma
CITIC Securities
CITIC Securities investment in Series B - Simcere Pharma
Hongcheng Capital
Hongcheng Capital investment in Series B - Simcere Pharma
Shanghai Creation Investment
Shanghai Creation Investment investment in Series B - Simcere Pharma
Yingke Capital
Yingke Capital investment in Series B - Simcere Pharma
Tianhui Chuangtou
Tianhui Chuangtou investment in Series B - Simcere Pharma
GP Capital
GP Capital investment in Series B - Simcere Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-02-26 | Amwise Diagnostic | Simcere Pharma investment in Series B - Amwise Diagnostic | 10 M USD |
| 2016-10-17 | Veritas Genetics | Simcere Pharma investment in Series B - Veritas Genetics | 30 M USD |
Official Site Inspections
http://www.simcere.com Semrush global rank: 1.97 M Semrush visits lastest month: 10.87 K
- Host name: 58.213.132.85
- IP address: 58.213.132.85
- Location: Nanjing China
- Latitude: 32.0617
- Longitude: 118.7778
- Timezone: Asia/Shanghai
More informations about "Simcere Pharma"
Simcere
Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D. We are committed to "providing today's patients with medicines of the future" โฆSee details»
Simcere Pharma - Crunchbase Company Profile & Funding
Simcere Pharma develops and supplies pharmaceuticals targeting cancer treatment, focusing on innovative therapies to address oncological diseases. Central Nervous System The company โฆSee details»
Simcere - ๅ ๅฃฐ่ฏไธๅฎ็ฝ
ๅ ๅฃฐ่ฏไธๆฏไธๅฎถๅๆฐไธ็ ๅ้ฉฑๅจ็ๅถ่ฏๅ ฌๅธ๏ผไธๆณจไบ่ฟ็คใ็ฅ็ป็ณป็ปใ่ช่บซๅ ็ซๅๆๆๆ้ขๅ็่ฏ็ฉๅผๅใSee details»
Simcere Pharmaceutical Group Limited
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor . On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere โฆSee details»
Simcere Pharmaceutical - Wikipedia
Simcere Pharmaceutical Group or Simcere Pharmaceutical (Chinese: ๅ ๅฃฐ่ฏไธ, SEHK: 2096) is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market.Its focus โฆSee details»
Simcere Pharmaceutical Group - LinkedIn
Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D and committed to synergistic innovation. It has established the State Key โฆSee details»
Org Chart Simcere Pharmaceutical - The Official Board
Organizational Chart of Simcere Pharmaceutical. Simcere Pharmaceutical www.en.simcere.com. has 11 executives +852 258 556 6666; Add an executive. Simcere Pharmaceutical News . โฆSee details»
Simcere Pharmaceutical Group Limited
Jun 13, 2023 Simcere Pharmaceutical Group Limited (2096.HK) is an innovation and R&D-driven pharmaceutical company. The Company focuses on three therapeutic areas, oncology, โฆSee details»
Simcere Pharma - Contacts, Employees, Board Members
Simcere Pharma has 1 board member or advisor, Mark B. Benjamin. Contacts. Edit Contacts Section. Job Department. Protected Content. Chief Operating Officer (COO) US & Europe, โฆSee details»
Simcere
Simcere has been continuously expanding its R&D investments. In 2022, its R&D investment was more than CNY 1.7 billion, accounting for 27.3% of the sales revenue. With five R&D centers โฆSee details»
Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue. Release โฆSee details»
Simcere
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor . 2024-09-02. read more. 6,500+ Staff. 40+ Current Brands of Products. 50+ Innovative Product โฆSee details»
Chinaโs Simcere Pharmaceutical Advances At Home After Exit
Sep 12, 2021 Simcere successfully listed in Hong Kong last year, raising HK$3.57 billion ($460.6 million) in Hong Kong from the sale of 261 million shares at HK$13.70 apiece on Oct. 27.See details»
Merck and Simcere Sign Agreement to Establish Pioneering China โฆ
Jul 21, 2011 Partnership Focused on Providing Significantly Enhanced Access to Quality Medicines for Chinese Patients Merck & Co., Inc., Whitehouse Station, N.J., (NYSE:MRK), โฆSee details»
Simcere Pharmaceutical Group Announces Sponsored Research โฆ
Jun 12, 2023 For more information, please visit massgeneralbrigham.org. About Simcere Pharmaceutical Group. Simcere Pharmaceutical Group Limited (2096.HK) is an innovation โฆSee details»
Simcere Receives FDA Clearance of Investigational New Drug โฆ
Oct 27, 2022 It is the second IND approval Simcere obtained in the US this year. In addition, the IND application of SIM0237 in China was accepted by the National Medical Products โฆSee details»
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
Sep 29, 2022 Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group๏ผ2096.HK), an innovation and R&D-driven โฆSee details»
Simcere
Jun 13, 2023 Simcere Pharmaceutical Group Limited (2096.HK) is an innovation and R&D-driven pharmaceutical company. The Company focuses on three therapeutic areas, oncology, โฆSee details»
Simcere
Dec 28, 2020 Simcere continued to apply a โdual-drive" model of innovation, which combined in-house R&D with international collaborations. In March, Simcere signed a strategic partnership โฆSee details»